Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.

Psychennex will take advantage of Australia’s new psychedelics regulations through clinical research programs and service delivery, including MDMA-assisted psychotherapy for PTSD, psilocybin-assisted psychotherapy for TRD and psilocybin-assisted psychotherapy for GAD once approved.

The new business will gather all of Incannex’s psychedelic-related assets, including IP from PsiGAD clinical trials and licensing of future psychedelic trials; product development (see the company’s agreement with Catalent on cGMP psilocybin, plus virtual reality-augmented psychedelic-assisted psychotherapy😉 distribution contracts for …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.